Hematologic Oncology | Specialty

Combinations Continue to Push CLL Field Forward

February 19th 2018

Jacqueline C. Barrientos, MD, discusses recent combination trials in CLL, and emerging agents in the pipeline.

MCL Expert Highlights Recent Advancements in Field

February 16th 2018

Peter Martin, MD, reflects on the MCL data presented at the 2017 ASH Annual Meeting, and shares his insight on the future of clinical trials in the disease.

FDA Panel to Review Blinatumomab Application for MRD-positive ALL

February 16th 2018

The FDA's Oncologic Drugs Advisory Committee is slated to review a supplemental biologics license application for the use of blinatumomab for the treatment of patients with minimal residual disease-positive B-cell precursor acute lymphoblastic leukemia.

FDA Grants Priority Review to Ivosidenib for IDH1+ AML

February 15th 2018

The FDA has granted a priority review designation to ivosidenib (AG-120) for the treatment of patients with relapsed/refractory IDH1-mutant acute myeloid leukemia.

Dr. McCloskey Discusses IDH Inhibitors in AML

February 14th 2018

James K. McCloskey II, MD, medical oncologist, Division of Leukemia and the Adult Blood and Marrow Stem Cell Transplantation Program, John Theurer Cancer Center, discusses IDH inhibitors in acute lymphoblastic leukemia (AML).

Dr. Wang Discusses Treatment Options for FLT3-Mutated AML

February 9th 2018

Eunice Wang, MD, chief, Leukemia Service, professor of Oncology, Departments of Medicine and Immunology, Roswell Park Cancer Institute, discusses treatment options for patients with FLT3-mutated acute myeloid leukemia.

Expert Discusses Letermovir Approval for CMV Prophylaxis Post-Transplantation

February 7th 2018

Miguel Perales, MD, discusses the impact of the FDA approval of letermovir for patients with CMV prophylaxis following transplantation.

Frontline Venetoclax Shows Promise in Elderly AML Patients

February 7th 2018

Venetoclax (Venclexta) in combination with a hypomethylating agent induced complete remissions in 61% of patients aged 65 years or older with previously untreated acute myeloid leukemia.

Vemurafenib/Rituximab Combo Reaches 100% CR Rate in Hairy Cell Leukemia

February 6th 2018

Enrico Tiacci, MD, discusses the high potential with the combination of vemurafenib and rituximab in relapsed/refractory patients with hairy cell leukemia.

Dr. Mannis on Targeted Agents in the Treatment of Patients With AML

February 6th 2018

Gabriel Mannis, MD, assistant professor, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the FDA approval and potential approval of 2 new agents that will provide a more nuanced treatment approach for patients with acute myeloid leukemia (AML).

Dr. Koprivnikar Discusses FLT3 Inhibitors in Hematologic Malignancies

January 31st 2018

Jamie Koprivnikar, MD, medical oncologist, John Theurer Cancer Center, discusses FLT3 inhibitors in the treatment of hematologic malignancies.

FDA Puts Clinical Holds on Trials of BPX-501

January 31st 2018

The FDA has halted 4 US studies of BPX-501, a novel cellular immunotherapy for cancers and orphan inherited blood disorders, after 3 patients developed encephalopathy possibly related to treatment with BPX-501.

Dr. Wang Discusses Crenolanib Plus Chemotherapy in AML

January 30th 2018

Eunice Wang, MD, chief, Leukemia Service, professor of Oncology, Departments of Medicine and Immunology, Roswell Park Cancer Institute, discusses the combination of crenolanib and cytarabine/anthracycline chemotherapy in patients with acute myeloid leukemia.

Dr. Skarbnik on Impact of Checkpoint Inhibition Following ASCT

January 30th 2018

Alan Skarbnik, MD, staff physician, department of Bone Marrow Transplant, department of Lymphoma, John Theurer Cancer Center, discusses the preliminary safety and efficacy data for checkpoint inhibition with ipilimumab (Yervoy) and nivolumab (Opdivo) following autologous stem cell transplantation in high-risk hematologic malignancies.

Acute Lymphoblastic Leukemia: The Future of Treatment

January 30th 2018

Role of CAR T-Cell Therapy in Relapsed/Refractory ALL

January 30th 2018

Relapsed/Refractory ALL: Inotuzumab Ozogamicin

January 30th 2018

Relapsed/Refractory ALL: Evaluating Novel Agents

January 30th 2018

Approaching Treatment for Relapsed/Refractory ALL

January 30th 2018

MRD-Positive ALL: Personal Approaches to Treatment

January 30th 2018